WO2011057208A3 - Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction - Google Patents
Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction Download PDFInfo
- Publication number
- WO2011057208A3 WO2011057208A3 PCT/US2010/055861 US2010055861W WO2011057208A3 WO 2011057208 A3 WO2011057208 A3 WO 2011057208A3 US 2010055861 W US2010055861 W US 2010055861W WO 2011057208 A3 WO2011057208 A3 WO 2011057208A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- compositions
- aryl
- treating neurological
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Furan Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2012005248A MX2012005248A (en) | 2009-11-06 | 2010-11-08 | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction. |
AU2010314891A AU2010314891A1 (en) | 2009-11-06 | 2010-11-08 | Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
RU2012121631/15A RU2012121631A (en) | 2009-11-06 | 2010-11-08 | Aryl and heteroaryl sulfones as allosteric potentiating agents for mGluR4, compositions and methods for treating neurological dysfunctions |
CN2010800589711A CN103079570A (en) | 2009-11-06 | 2010-11-08 | Aryl and heteroaryl sulfones as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
CA2780128A CA2780128A1 (en) | 2009-11-06 | 2010-11-08 | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
BR112012010738A BR112012010738A2 (en) | 2009-11-06 | 2010-11-08 | "Aryl and heteroaryl sulfones as allosteric mglur4 enhancers, compositions and methods of treating neurological dysfunction" |
EP10829242A EP2498781A2 (en) | 2009-11-06 | 2010-11-08 | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US13/508,535 US8912336B2 (en) | 2009-11-06 | 2010-11-08 | Aryl and heteroaryl sulfones as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
JP2012538064A JP2013510178A (en) | 2009-11-06 | 2010-11-08 | Aryl and heteroaryl sulfones as mGluR4 allosteric enhancers, compositions, and methods of treating neurological dysfunction |
IL219568A IL219568A0 (en) | 2009-11-06 | 2012-05-03 | Aryl and heteroaryl sulfones, as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25885609P | 2009-11-06 | 2009-11-06 | |
US61/258,856 | 2009-11-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011057208A2 WO2011057208A2 (en) | 2011-05-12 |
WO2011057208A3 true WO2011057208A3 (en) | 2014-03-20 |
Family
ID=43970815
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/055861 WO2011057208A2 (en) | 2009-11-06 | 2010-11-08 | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
Country Status (12)
Country | Link |
---|---|
US (1) | US8912336B2 (en) |
EP (1) | EP2498781A2 (en) |
JP (1) | JP2013510178A (en) |
KR (1) | KR20120115252A (en) |
CN (1) | CN103079570A (en) |
AU (1) | AU2010314891A1 (en) |
BR (1) | BR112012010738A2 (en) |
CA (1) | CA2780128A1 (en) |
IL (1) | IL219568A0 (en) |
MX (1) | MX2012005248A (en) |
RU (1) | RU2012121631A (en) |
WO (1) | WO2011057208A2 (en) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2751176A1 (en) | 2009-01-28 | 2010-08-05 | Vanderbilt University | Substituted 1,1,3,3-tetraoxidobenzo[d][1,3,2]dithiazoles as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US8759377B2 (en) | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
WO2016115272A1 (en) | 2015-01-13 | 2016-07-21 | Vanderbilt University | Benzothiazole and benzisothiazole-substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2016123627A1 (en) | 2015-01-30 | 2016-08-04 | Vanderbilt University | Isoquiniline and napthalene-substituted compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction |
US10526323B2 (en) | 2015-01-30 | 2020-01-07 | Vanderbilt University | Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US9987242B2 (en) | 2015-05-05 | 2018-06-05 | Northwestern University | Treatment of Levodopa-induced Dyskinesias |
AR105556A1 (en) * | 2015-08-03 | 2017-10-18 | Hoffmann La Roche | ETHYLENE DERIVATIVES |
US10710997B2 (en) | 2016-09-01 | 2020-07-14 | Vanderbilt University | Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
US10294222B2 (en) | 2016-09-01 | 2019-05-21 | Vanderbilt University | Benzomorpholine and benzomorpholine-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2018089544A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline amine compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
WO2018089546A1 (en) | 2016-11-08 | 2018-05-17 | Vanderbilt University | Isoquinoline ether compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
CN108148054B (en) * | 2016-12-05 | 2021-01-08 | 中国科学院大连化学物理研究所 | Pyridyl bridged chiral oxazoline compound and synthetic method thereof |
US11319304B2 (en) | 2017-06-28 | 2022-05-03 | Vanderbilt University | Pyridine quinoline compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
SG11202001264UA (en) | 2017-08-16 | 2020-03-30 | Univ Vanderbilt | Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
CN112409251B (en) * | 2020-11-26 | 2022-07-05 | 成都百泉生物医药科技有限公司 | Omeprazole process impurity and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693652A (en) * | 1991-09-30 | 1997-12-02 | Eisai Co., Ltd. | Benzimidazoles for ischemic heart conditions |
WO2005007096A2 (en) * | 2003-07-11 | 2005-01-27 | Merck & Co., Inc. | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3326753A (en) * | 1961-02-23 | 1967-06-20 | Merck & Co Inc | Benzimidazole anthelmintic compositions and method of use |
US3429890A (en) * | 1964-12-31 | 1969-02-25 | Merck & Co Inc | Certain 2-thiazolylbenzimidazole-1-oxy derivatives |
DE2130030A1 (en) * | 1971-06-18 | 1972-12-21 | Bayer Ag | Fungicidal and bactericidal agents |
FR2751649B1 (en) | 1996-07-26 | 1998-08-28 | Adir | NOVEL DERIVATIVES OF BENZIMIDAZOLE, BENZOXAZOLE AND BENZOTHIAZOLE, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
GB9914825D0 (en) | 1999-06-24 | 1999-08-25 | Smithkline Beecham Spa | Novel compounds |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
EP1341768A1 (en) | 2000-12-07 | 2003-09-10 | AstraZeneca AB | Therapeutic benzimidazole compounds |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
RU2004126671A (en) | 2002-02-06 | 2005-04-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | HETEROARYL COMPOUNDS USEFUL AS GSK-3 INHIBITORS |
RU2329261C2 (en) | 2003-12-29 | 2008-07-20 | Баниу Фармасьютикал Ко., Лтд. | New 2-heteroaryl-substitute benzimidazole derivative |
ES2318556T3 (en) | 2004-11-02 | 2009-05-01 | Pfizer, Inc. | DERIVATIVES OF SULFONIL BENCIMIDAZOL. |
GB0505725D0 (en) | 2005-03-19 | 2005-04-27 | Merck Sharp & Dohme | Therapeutic agents |
JP5340729B2 (en) | 2005-06-13 | 2013-11-13 | メルク シャープ エンド ドーム リミテッド | Therapeutic agent |
ATE484497T1 (en) | 2006-03-06 | 2010-10-15 | Raqualia Pharma Inc | SULFONYLBENZIMIDAZOLE DERIVATIVES |
EP2004613A2 (en) | 2006-03-31 | 2008-12-24 | AstraZeneca AB | Bicyclic benzimidazole compounds and their use as metabotropic glutamate receptor potentiators |
EP2182935A1 (en) | 2007-08-02 | 2010-05-12 | F. Hoffmann-Roche AG | The use of benzamide derivatives for the treatment of cns disorders |
WO2009134754A1 (en) * | 2008-04-28 | 2009-11-05 | Janssen Pharmaceutica Nv | Benzoimidazole glycinamides as prolyl hydroxylase inhibitors |
-
2010
- 2010-11-08 CN CN2010800589711A patent/CN103079570A/en active Pending
- 2010-11-08 WO PCT/US2010/055861 patent/WO2011057208A2/en active Application Filing
- 2010-11-08 CA CA2780128A patent/CA2780128A1/en not_active Abandoned
- 2010-11-08 KR KR1020127014657A patent/KR20120115252A/en not_active Application Discontinuation
- 2010-11-08 AU AU2010314891A patent/AU2010314891A1/en not_active Abandoned
- 2010-11-08 RU RU2012121631/15A patent/RU2012121631A/en not_active Application Discontinuation
- 2010-11-08 US US13/508,535 patent/US8912336B2/en active Active
- 2010-11-08 MX MX2012005248A patent/MX2012005248A/en not_active Application Discontinuation
- 2010-11-08 EP EP10829242A patent/EP2498781A2/en not_active Withdrawn
- 2010-11-08 BR BR112012010738A patent/BR112012010738A2/en not_active IP Right Cessation
- 2010-11-08 JP JP2012538064A patent/JP2013510178A/en not_active Withdrawn
-
2012
- 2012-05-03 IL IL219568A patent/IL219568A0/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5693652A (en) * | 1991-09-30 | 1997-12-02 | Eisai Co., Ltd. | Benzimidazoles for ischemic heart conditions |
WO2005007096A2 (en) * | 2003-07-11 | 2005-01-27 | Merck & Co., Inc. | Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator |
Non-Patent Citations (2)
Title |
---|
NISWENDER ET AL.: "Positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4): Part I. Discovery of pyrazolo[3,4-d]pyrimidines as novel mGIuR4 positive allosteric modulators.", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 18, no. 20, 2008, pages 5626 - 5630, XP025562122 * |
TOYONO ET AL.: "Expression of the metabotropic glutamate receptor, mglur4a, in the taste hairs of taste buds in rat gustatory papillae.", ARCHIVES OF HISTOLOGY AND CYTOLOGY, vol. 65, no. 1, 2002, pages 91 - 96, XP055136127 * |
Also Published As
Publication number | Publication date |
---|---|
RU2012121631A (en) | 2013-12-20 |
CA2780128A1 (en) | 2011-05-12 |
MX2012005248A (en) | 2012-06-14 |
WO2011057208A2 (en) | 2011-05-12 |
CN103079570A (en) | 2013-05-01 |
JP2013510178A (en) | 2013-03-21 |
KR20120115252A (en) | 2012-10-17 |
US8912336B2 (en) | 2014-12-16 |
BR112012010738A2 (en) | 2019-09-24 |
EP2498781A2 (en) | 2012-09-19 |
US20120245185A1 (en) | 2012-09-27 |
IL219568A0 (en) | 2012-06-28 |
AU2010314891A1 (en) | 2012-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011057208A3 (en) | Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
MX2012013031A (en) | Heterocyclic sulfone mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction. | |
EP2490529A4 (en) | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
TN2012000400A1 (en) | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as mglur4 allosteric potentiators, compounds, and methods of treating neurological dysfunction | |
SG178999A1 (en) | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
WO2009100294A3 (en) | Amide derivatives as positive allosteric modulators and methods of use thereof | |
WO2008152099A3 (en) | Aryl/hetarylamides as modulators of the ep2 receptor | |
WO2009145996A3 (en) | Amide derivatives as positive allosteric modulators and methods of use thereof | |
WO2008070462A3 (en) | N-oxides of 4,5-epoxy-morphinanium analogs | |
WO2009012275A9 (en) | Pyridone gpr119 g protein-coupled receptor agonists | |
WO2009140166A3 (en) | Oxazolobenzimidazole derivatives | |
WO2010008831A3 (en) | Compounds and methods for modulating g protein-coupled receptors | |
WO2008064353A3 (en) | 7,8-saturated-4,5-epoxy-morphinanium analogs | |
WO2006123255A3 (en) | Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors | |
WO2010123930A3 (en) | Chemosensory receptor ligand-based therapies | |
MX2009012749A (en) | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor). | |
WO2008097461A3 (en) | Hepcidin and hepcidin antibodies | |
WO2010115552A8 (en) | Bispecific anti-erbb-3/anti-c-met antibodies | |
WO2009082038A3 (en) | Ampa receptor antagonists and zonisamide for epilepsy | |
WO2008040649A3 (en) | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators | |
WO2007109279A3 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
WO2008152093A3 (en) | Diaminopyrimidines as modulators of the ep2 receptor | |
WO2007053765A3 (en) | Substituted cycloalkylpyrrolones as allosteric modulators of glucokinase | |
ZA202001321B (en) | Indazole compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | |
WO2013170072A3 (en) | Compounds for the treatment of neurological disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080058971.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10829242 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 219568 Country of ref document: IL |
|
ENP | Entry into the national phase |
Ref document number: 2780128 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2012/005248 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012538064 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010314891 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 4343/DELNP/2012 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012121631 Country of ref document: RU Ref document number: 2010829242 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2010314891 Country of ref document: AU Date of ref document: 20101108 Kind code of ref document: A Ref document number: 20127014657 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13508535 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012010738 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012010738 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120507 |